Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push

(2013) R. Shapiro   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

(2013) Stephen Jolles et al.   CLINICAL IMMUNOLOGY

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

(2012) Richard L. Wasserman et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

(2012) Richard L. Wasserman   JOURNAL OF CLINICAL IMMUNOLOGY

Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies

(2011) M. Borte et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

(2011) Richard L. Wasserman et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

(2011) Michael Borte et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Effectiveness of Immunoglobulin Replacement Therapy on Clinical Outcome in Patients with Primary Antibody Deficiencies: Results from a Multicenter Prospective Cohort Study

(2011) Isabella Quinti et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

(2011) Melvin Berger et al.   SOUTHERN MEDICAL JOURNAL

Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies

(2010) Marc J. Meth et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseases

(2010) J. N. Moy et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

(2010) Jordan S. Orange et al.   CLINICAL IMMUNOLOGY

Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

(2010) John B. Hagan et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Subcutaneous immunoglobulin: opportunities and outlook

(2009) S. Misbah et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers

(2009) George Harb et al.   CURRENT MEDICAL RESEARCH AND OPINION

Recombinant Human Hyaluronidase-Enabled Subcutaneous Pediatric Rehydration

(2009) C. H. Allen et al.   PEDIATRICS

Subcutaneous Administration of IgG

(2008) Melvin Berger   IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA

Quality of Life and Health-Care Resource Utilization Among Children with Primary Immunodeficiency Receiving Home Treatment with Subcutaneous Human Immunoglobulin

(2008) Anders Fasth et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

(2008) Mark R. Stein et al.   JOURNAL OF CLINICAL IMMUNOLOGY